Pomalidomide Added to the Regimen in First Relapse Extends PFS in Multiple Myeloma.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 2, p. 42
- By:
- Publication type:
- Article
Works matching IS 21534888 AND DT 2018 AND VI 9 AND IP 2
Results: 28
1
2
Next-Generation Sequencing Could Help Treatment Decisions in Acute Myeloid Leukemia.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 2, p. 41
- By:
- Publication type:
- Article
3
Nelarabine Therapy Up Front Boosts Survival in T-Cell Leukemia and Lymphoma.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 2, p. 41
- By:
- Publication type:
- Article
4
Timing of Palliative Care Consults Affects Healthcare Utilization in Elderly Patients with Pancreatic Cancer.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 2, p. 40
- By:
- Publication type:
- Article
5
Discussing Costs with Your Patient Can Reduce Financial Toxicity.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 2, p. 39
- By:
- Publication type:
- Article
6
Cost of Treating Colorectal Cancer in the United States Double That of Canada, with No Survival Benefit.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 2, p. 38
- By:
- Publication type:
- Article
7
PARP Inhibitors Least Cost-Effective as Maintenance Therapy in Advanced Ovarian Cancer.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 2, p. 37
- By:
- Publication type:
- Article
8
Next-Generation Sequencing More Cost-Effective and Faster Than Single-Gene Testing.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 2, p. 37
- By:
- Publication type:
- Article
9
High Tumor Microsatellite Instability a Marker for Lynch Syndrome, More Common Condition Than Generally Expected.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 2, p. 36
- By:
- Publication type:
- Article
10
With Access to Care, Black Men in the United States Have Same Prostate Cancer Outcomes as White Men.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 2, p. 35
- By:
- Publication type:
- Article
11
NCCN Drug Affordability Ratings Miss the Mark in Lung Cancer.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 2, p. 34
- By:
- Publication type:
- Article
12
Pembrolizumab as a First-Line Standard-of-Care Option in Advanced Non--Small-Cell Lung Cancer.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 2, p. 33
- By:
- Publication type:
- Article
13
Bevacizumab plus Chemotherapy Approved for Several Types of Ovarian Cancer.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 2, p. 29
- Publication type:
- Article
14
LOXO-292 Highly Effective in RET-Positive Cancers.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 2, p. 29
- By:
- Publication type:
- Article
15
Ivosidenib a New Standard of Care for Relapsed or Refractory AML with IDH1 Mutation.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 2, p. 28
- By:
- Publication type:
- Article
16
Keytruda Receives 2 New Indications: Metastatic Cervical Cancer and Relapsed Mediastinal Large B-Cell Lymphoma.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 2, p. 27
- Publication type:
- Article
17
Venclexta Indicated for CLL or SLL, Alone or in Combination with Rituxan.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 2, p. 27
- Publication type:
- Article
18
Tafinlar-Mekinist Combination Approved for Metastatic Thyroid Cancer with BRAF V600E Mutation.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 2, p. 27
- Publication type:
- Article
19
Kymriah Approved for Adults with Relapsed or Refractory Large B-Cell Lymphoma.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 2, p. 26
- Publication type:
- Article
20
Cell-Free DNA Assays Could Result in a New Blood Test for Early Detection of Cancer.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 2, p. 26
- By:
- Publication type:
- Article
21
Investigational CAR T-Cell Therapy, bb2121, Shows Durable Responses in Relapsed or Refractory Multiple Myeloma.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 2, p. 24
- By:
- Publication type:
- Article
22
Immunotherapy Combinations "Raising the Bar".
- Published in:
- 2018
- By:
- Publication type:
- Proceeding
23
Less Is More: 6 Months of Trastuzumab Treatment Equivalent to 12 Months in HER2-Positive Breast Cancer.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 2, p. 15
- By:
- Publication type:
- Article
24
First-in-Class Antibody-Drug Conjugate Effective in HER2-Negative Metastatic Breast Cancer.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 2, p. 14
- By:
- Publication type:
- Article
25
IMPACT: Matching Treatment and Molecular Testing Extends Survival in Advanced Cancer.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 2, p. 1
- By:
- Publication type:
- Article
26
Chemotherapy Can Be Spared in Many Patients with Early Breast Cancer: Devil Is in the Details.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 2, p. 1
- By:
- Publication type:
- Article
27
CAR T-Cell Therapy Yields Impressive Responses in Aggressive Non-Hodgkin Lymphoma.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 2, p. 1
- By:
- Publication type:
- Article
28
Precision Medicine and Immunotherapy Highlighted at ASCO 2018.
- Published in:
- 2018
- By:
- Publication type:
- Proceeding